PT Soho Global Health Tbk (SOHO.JK)
IDR 635.0
(0.0%)
IDR 635.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 538.94 Billion IDR | -0.12% |
| 2022 | 525.12 Billion IDR | -32.37% |
| 2021 | 762.81 Billion IDR | 143.71% |
| 2020 | 335.64 Billion IDR | 15.84% |
| 2019 | 295.82 Billion IDR | 65.01% |
| 2018 | 161.36 Billion IDR | 31.13% |
| 2017 | 124.98 Billion IDR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 143.22 Billion IDR | -21.31% |
| 2024 Q1 | 174.84 Billion IDR | 25.0% |
| 2024 Q3 | 154.04 Billion IDR | 16.0% |
| 2023 Q2 | 132.59 Billion IDR | 47.93% |
| 2023 FY | - IDR | -0.12% |
| 2023 Q4 | 132.3 Billion IDR | -14.75% |
| 2023 Q3 | 155.19 Billion IDR | 17.05% |
| 2023 Q1 | 89.63 Billion IDR | -9.3% |
| 2022 Q4 | 98.82 Billion IDR | -25.14% |
| 2022 Q3 | 132 Billion IDR | 78.02% |
| 2022 Q2 | 74.15 Billion IDR | -62.14% |
| 2022 Q1 | 195.85 Billion IDR | 301.31% |
| 2022 FY | - IDR | -32.37% |
| 2021 Q2 | 180.98 Billion IDR | -0.5% |
| 2021 Q3 | 307.8 Billion IDR | 70.08% |
| 2021 Q1 | 181.88 Billion IDR | 337.75% |
| 2021 FY | - IDR | 143.71% |
| 2021 Q4 | 48.8 Billion IDR | -84.14% |
| 2020 Q2 | 131 Billion IDR | -37.61% |
| 2020 Q4 | 41.55 Billion IDR | 141.25% |
| 2020 Q3 | -100.73 Billion IDR | -176.89% |
| 2020 Q1 | 209.98 Billion IDR | 164.18% |
| 2020 FY | - IDR | 15.84% |
| 2019 Q4 | 79.48 Billion IDR | 0.0% |
| 2019 Q1 | 95.48 Billion IDR | 0.0% |
| 2019 FY | - IDR | 65.01% |
| 2018 FY | - IDR | 31.13% |
| 2017 FY | - IDR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| PT Enseval Putera Megatrading Tbk. | 1081.16 Billion IDR | 50.152% |
| PT Itama Ranoraya Tbk | 32.71 Billion IDR | -1547.308% |
| PT Kimia Farma (Persero) Tbk | -1223.64 Billion IDR | 144.044% |
| PT Millennium Pharmacon International Tbk | 124.5 Billion IDR | -332.86% |